Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion
ORGANISM(S): Mus Musculus (mouse)
DISEASE(S): Acute Leukemia
SUBMITTER: François Mercier
LAB HEAD: Francois Mercier
PROVIDER: PXD054402 | Pride | 2024-08-08
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
M-TMT-F1.raw | Raw | |||
M-TMT-F2.raw | Raw | |||
M-TMT-F3.raw | Raw | |||
M-TMT-F4.raw | Raw | |||
M-TMT-F5.raw | Raw |
Items per page: 1 - 5 of 10 |
Blood advances 20241001 20
<h4>Abstract</h4>For several decades, induction therapy with nucleoside analogs, in particular cytarabine (Ara-C) and, to a lesser extent, fludarabine, has been the standard of care for patients diagnosed with acute myeloid leukemia (AML). However, the antitumor efficacy of nucleoside analogs is often limited by intrinsic and acquired drug resistance, thereby leading to poor therapeutic response and suboptimal clinical outcomes. In this study, we used genome-wide CRISPR-based pharmacogenomic scr ...[more]